Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
GDC-0927
i
Other names:
GDC-0927, SRN-927, RG6047, ARN-927, RO7056119, SERD 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Roche
Drug class:
Selective estrogen receptor degrader
Related drugs:
‹
fulvestrant (57)
elacestrant (9)
SAR439859 (9)
AZD9833 (7)
LY3484356 (7)
OP-1250 (7)
SCR-6852 (4)
GDC-9545 (4)
ZN-c5 (3)
AZD9496 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
AND019 (0)
DZD3969 (0)
LSZ102 (0)
SHR9549 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
fulvestrant (57)
elacestrant (9)
SAR439859 (9)
AZD9833 (7)
LY3484356 (7)
OP-1250 (7)
SCR-6852 (4)
GDC-9545 (4)
ZN-c5 (3)
AZD9496 (2)
G1T48 (2)
LX-039 (1)
SCR6106 (1)
D-0502 (1)
AND019 (0)
DZD3969 (0)
LSZ102 (0)
SHR9549 (0)
GDC-0810 (0)
EGL-5385-C-1701 (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
ER positive
HER2 Negative Breast Cancer
ER positive
HER2 Negative Breast Cancer
GDC-0927
Sensitive: C2 – Inclusion Criteria
GDC-0927
Sensitive
:
C2
GDC-0927
Sensitive: C2 – Inclusion Criteria
GDC-0927
Sensitive
:
C2
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
ER positive + ESR1 mutation
HER2 Negative Breast Cancer
GDC-0927
Sensitive: C3 – Early Trials
GDC-0927
Sensitive
:
C3
GDC-0927
Sensitive: C3 – Early Trials
GDC-0927
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login